The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of olaparib in combination with capecitabine-based chemoradiation (CRT) in patients (pts) with locally advanced pancreatic cancer (LAPC).
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Medivir (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); MiNA Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre
Other Relationship - Genmab; Genmab; Genmab; Genmab
 
Martin McKinlay Eatock
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis
 
Liz-Anne Lewsley
No Relationships to Disclose
 
Caroline Kelly
No Relationships to Disclose
 
Elaine McCartney
No Relationships to Disclose
 
Aileen Duffton
No Relationships to Disclose
 
Peter Houston
No Relationships to Disclose
 
Claire Harrison
No Relationships to Disclose
 
Colin Purcell
No Relationships to Disclose
 
Miranda Ashton
No Relationships to Disclose
 
Alanna Morton
No Relationships to Disclose
 
Jill Graham
No Relationships to Disclose
 
Anthony J. Chalmers
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Tesaro; Tesaro; Tesaro; Tesaro
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Fiona Thomson
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Merck; Merck; Merck; Merck
Consulting or Advisory Role - Bionomics; Bionomics; Bionomics; Bionomics
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Bionomics; Bionomics; Bionomics; Bionomics
 
Chantevy Pou
No Relationships to Disclose
 
Alan Bilsland
No Relationships to Disclose
 
Susie Cooke
No Relationships to Disclose
 
David McIntosh
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis
Speakers' Bureau - Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis
 
Derek B. Grose
No Relationships to Disclose